Conference Coverage

Melanoma advances make chemo third-tier therapy


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO – With new targeted therapies and immunotherapies for metastatic melanoma, chemotherapy is now a thirdtier option for these patients, according to melanoma expert Dr. Lynn M. Schuchter, of the University of Pennsylvania, Philadelphia.

Dr. Schuchter discusses new practice-changing approaches in the treatment of melanoma in an interview at the annual meeting of the American Society of Clinical Oncology.

Recommended Reading

Ipilimumab plus surgery boosted advanced melanoma survival
MDedge Internal Medicine
One in four melanoma patients shun sunscreen
MDedge Internal Medicine
Are dermatologists falling behind the technology curve?
MDedge Internal Medicine
Melanoma increases in adolescents
MDedge Internal Medicine
Therapeutic combos make inroads in advanced melanoma
MDedge Internal Medicine
FDA: Tanning lamps should warn against skin cancer
MDedge Internal Medicine
FDA advisory panel nixes approval of drug-device for liver metastases
MDedge Internal Medicine
Dual immunotherapy scores rapid response in metastatic melanoma
MDedge Internal Medicine
Environmental Working Group deems 25% of sunscreens safe, effective
MDedge Internal Medicine
FDA approves two more drugs for advanced melanoma
MDedge Internal Medicine